Physician profile
Donald Budenz
NPI 1063455749
$17,106.89
in general payments reported to CMS, 2019-2025
9 companies · $84.41 in 2025
The $84.41 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $1,489 · 2021: $8,257 · 2022: $5,197 · 2023: $1,875 · 2025: $84.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,875 · Food and Beverage: $84.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,875.00 |
| Food and Beverage | $84.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $8,840.00 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,192.19 | 2019-2021 | |
| Alcon Vision LLC | $2,016.62 | 2022 | |
| Glaukos Corporation | $1,875.00 | 2023 | |
| Alcon Research LLC | $1,224.41 | 2022-2025 | |
| New World Medical,INC. | $706.67 | 2020-2021 | |
| Allergan, INC. | $119.85 | 2020 | |
| Ivantis, INC | $112.75 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Budenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.